DelveInsight reports that more than two key companies are actively developing over four therapeutic candidates for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Chronic Inflammatory Demyelinating Polyneuropathy Overview:
Chronic inflammatory demyelinating polyneuropathy (CIDP), also known as chronic inflammatory demyelinating polyradiculoneuropathy, is an autoimmune disorder that causes inflammation of the peripheral nerves and nerve roots. The condition involves damage to the myelin sheath and infiltration of immune cells, leading to progressive motor and sensory deficits. Patients often experience weakness in both proximal and distal muscles, numbness, tingling (paraesthesia), sensory ataxia, and, in severe cases, significant disability due to extensive demyelination and secondary axonal degeneration. CIDP develops gradually over more than two months and can present in relapsing, progressive, or monophasic forms.
Common symptoms include tingling sensations, gradual muscle weakness, loss of reflexes, balance issues, walking difficulties, and reduced sensation in the arms and legs, often starting with impaired pinprick perception. These symptoms emerge slowly over weeks to months and may worsen over time, affecting daily activities. As the disease progresses, muscle weakness can become more pronounced, further compromising mobility and coordination.
Request for a detailed insights report on Chronic Inflammatory Demyelinating Polyneuropathy pipeline insights
“Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market.
Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report
-
DelveInsight’s Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline report highlights an active landscape with over two companies developing more than four therapeutic candidates.
-
Key players such as Sanofi, Immunovant Sciences GmbH, and others are advancing novel therapies to improve treatment options for CIDP.
-
Promising pipeline candidates in development include Riliprubart, Batoclimab, and others.
-
Sanofi has initiated two global Phase 3 trials evaluating riliprubart, a potential first-in-class IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway. These studies aim to assess the safety and efficacy of riliprubart in adults with CIDP who have either not responded adequately to standard treatments or are on maintenance intravenous immunoglobulin therapy.
-
In June 2024, the FDA approved Vyvgart Hytrulo for adults with CIDP. This therapy combines efgartigimod alfa, a neonatal Fc receptor blocker, with hyaluronidase to enable subcutaneous administration. Approval was based on a multicenter study showing a statistically significant delay in clinical deterioration compared to placebo.
-
Earlier, in January 2024, the FDA approved HYQVIA as a maintenance therapy to prevent relapse of neuromuscular disability in adults with CIDP. As the first facilitated subcutaneous immunoglobulin (SCIG) therapy approved for CIDP, HYQVIA offers dosing intervals up to once monthly. The approval was supported by the Phase 3 ADVANCE-CIDP 1 study, which demonstrated a significant reduction in relapse rates compared to placebo.
Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Chronic Inflammatory Demyelinating Polyneuropathy Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Inflammatory Demyelinating Polyneuropathy treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Inflammatory Demyelinating Polyneuropathy market.
Download our free sample page report on Chronic Inflammatory Demyelinating Polyneuropathy pipeline insights
Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs
-
Riliprubart: Sanofi
-
Batoclimab: Immunovant Sciences GmbH
Chronic Inflammatory Demyelinating Polyneuropathy Companies
Over two leading companies are actively working on therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with Sanofi advancing the most progressed candidates, currently in Phase III clinical trials.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Chronic Inflammatory Demyelinating Polyneuropathy Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Inflammatory Demyelinating Polyneuropathy Therapies and Key Companies: Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials and advancements
Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapeutic Assessment
• Chronic Inflammatory Demyelinating Polyneuropathy Assessment by Product Type
• Chronic Inflammatory Demyelinating Polyneuropathy By Stage
• Chronic Inflammatory Demyelinating Polyneuropathy Assessment by Route of Administration
• Chronic Inflammatory Demyelinating Polyneuropathy Assessment by Molecule Type
Download Chronic Inflammatory Demyelinating Polyneuropathy Sample report to know in detail about the Chronic Inflammatory Demyelinating Polyneuropathy treatment market @ Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Chronic Inflammatory Demyelinating Polyneuropathy Current Treatment Patterns
4. Chronic Inflammatory Demyelinating Polyneuropathy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Chronic Inflammatory Demyelinating Polyneuropathy Late-Stage Products (Phase-III)
7. Chronic Inflammatory Demyelinating Polyneuropathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Inflammatory Demyelinating Polyneuropathy Discontinued Products
13. Chronic Inflammatory Demyelinating Polyneuropathy Product Profiles
14. Chronic Inflammatory Demyelinating Polyneuropathy Key Companies
15. Chronic Inflammatory Demyelinating Polyneuropathy Key Products
16. Dormant and Discontinued Products
17. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs
18. Chronic Inflammatory Demyelinating Polyneuropathy Future Perspectives
19. Chronic Inflammatory Demyelinating Polyneuropathy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/